Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact US
Clarity Pharmaceuticals
Clinical CRO
Overview
Contact US
Contributions
Contributors
Contributions
0 Contributors
1 / 0
1 / 0
1 Contributions
1 / 1
1 / 1
No authors found
Cu-67 SAR-bisPSMA
Clarity Receives US FDA Fast Track Designation for Treating Metastatic Castration-Resistant Prostate Cancer with Cu-67 SAR-bisPSMA
Clarity Pharmaceuticals
PR-02-25-NI-19
Feb 19, 2025
